Jul. 29 at 5:45 PM
$PPBT
$6M market cap.
$70B+ conservative addressable market estimate across oncology:
🧪 CM24: Anti-CEACAM1 mAb for pancreatic, gastric, biliary & CEACAM1+ tumors (~
$18–20B potential)
🧬 NT-219: STAT3 + IRS1/2 dual inhibitor for SCCHN, PD-1 resistant & KRAS+ tumors (~
$20–25B potential)
⚔️ CAPTN-3: Tri-specific antibody platform for 5T4+ tumors, modular expansion to EGFR/NKG2D (~
$25–35B potential)
Multi-modal assault on resistance, immune evasion & biomarker-driven precision.
Now focus turns to ESMO—data catalysts inbound..